Summary:
A 6-week randomized, multicenter, double-blind, parallel, fixed-dose study of MG01CI (Metadoxine Immediate-release/ Slow-release, Bilayer Caplet) 1400mg compared with placebo in adults with Attention Deficit/ Hyperactivity Disorder (ADHD)
Qualified Participants Must:
• Be between 18 and 55 years of age
•
Have a diagnosis of ADHD (no prior diagnosis required)
•
Be able to attend the clinic regularly and reliably
•
Not be taking megadoses of Vitamin B or Fish Oil
Qualified Participants May Receive:
Qualified participants will receive all research-related care, study medication and a $75 stipend for each visit. Prescreen visit is not compensated.